Gastroenterology

The decision makes budesonide oral suspension (Eohilia) the first and only FDA-approved oral therapy for patients ≥ 11 years of age with eosinophilic esophagitis.

Patients who switched from originator adalimumab to a biosimilar experienced more treatment-emergent adverse events compared to those who stuck with the biosimilar or the reference drug.

The literature review discusses the rising incidence of eosinophilic esophagitis, highlighting the efficacy of proton pump inhibitors, challenges in diagnosis, and the need for collaborative decision-making in its management.

Following the January 25, 2024 approval of dupilumab for eosinophilic esophagitis in patients 1-11 years of age, a trio of pediatric gastroenterologists shares their thoughts on the new indication, their anticipated priority of use, and potential hurdles to optimal treatment uptake.

Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.

A high intake of fish and vegetables at 1 year of age was associated with a lower risk of IBD, while consuming sugar-sweetened beverages was linked to a greater risk of developing IBD.

More than half of patients received return-IBD care via telehealth in the post-COVID period, and those with longer drive times were more likely to continue telehealth care.

We sat down with Evan Dellon, MD, MPH, to discuss the use of dupilumab in pediatric EoE patients, with the agent gaining FDA approval as the first and only indication for this patient population on January 25, 2024.

Interventions designed to improve mood, especially psychological therapy, may also have notable effects on C-reactive protein, fecal calprotectin, and other inflammatory biomarkers in IBD.

Findings from the retrospective cohort study suggest an increased prevalence of advanced kidney disease among individuals with Crohn disease and ulcerative colitis.

We sat down with Julie Khlevner, MD, to discuss new efficacy endpoint data from the phase 3 study used to support the FDA approval of linaclotide for pediatric functional constipation.

Patients ≥ 65 years of age experienced similar rates of remission and adverse events compared to their younger counterparts, with no significant difference in change in renal function observed between the 2 groups.

Results confirmed the long-term efficacy of ustekinumab maintenance in patients with ulcerative colitis, demonstrating consistent rates of symptomatic remission and endoscopic improvement with no new safety signals.

The new data was published in The Lancet Gastroenterology & Hepatology and highlighted additional efficacy endpoints from the study used to support linaclotide’s FDA approval in 2023.

Participants given omadacycline had high fecal concentrations with a distinct microbiome profile compared to those in the vancomycin group, with study results calling attention to the importance of antibiotics’ impact on the gut microbiome.

Our December 2023 Gastroenterology Month in Review features a pair of American Gastroenterological Association guidelines and articles from the fourth installment of Qazi Corner.

Katie Falloon, MD, discusses findings from the SEQUENCE study, the importance of treatment positioning, and what direct data from head-to-head studies contributes to this understanding.

Shubha Bhat, PharmD, MS, BCACP describes the ELEVATE UC program supporting the FDA approval of etrasimod and the current understanding of treatment positioning between etrasimod and ozanimod.

The guideline includes 9 conditional recommendations to support practitioners in the management of pouchitis and inflammatory pouch disorders.

The past year has seen a multitude of FDA approvals, ranging from IL-23 and JAK inhibitors to biologics and subcutaneous treatment administrations, that have helped redefine what it means to treat IBD.

Adding navy beans to one’s usual diet may be a viable dietary strategy for modulating the gut microbiome and regulating host markers associated with metabolic obesity and colorectal cancer.

The NDA submission was supported by positive data from the phase 3 PHALCON-NERD-301 study and has been assigned a standard 10-month review with a PDUFA target action date of July 19, 2024.

The final quarterly issue of the year touches on head-to-head trial data, a new treatment for erosive esophagitis, an ulcerative colitis agent, and the latest ACG recommendations for Celiac disease.e.

An expert reviews the updated recommendations of the American College of Gastroenterology guidelines on the evaluation and management of celiac disease.

While more studies are needed to ensure the safety of long-term therapy with PCABs, this study establishes a role for the use of vonoprazan in the healing and maintenance of healing in patients with erosive esophagitis.

Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.

The S1PR modulators are currently positioned to serve as a great treatment option for patients with moderate disease who are hesitant to escalate to a biologic treatment.

The guideline was developed by a multidisciplinary panel and consists of 11 conditional recommendations for the use of biomarkers in the management of Crohn disease.

Investigators ranked ChatGPT responses to healthcare professional-oriented questions about IBD as more useful and reliable than the model’s responses to patient-oriented questions.

Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab.